Lymphomatoid Granulomatosis (LYG)

Categories: Blood diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lymphomatoid Granulomatosis

MalaCards integrated aliases for Lymphomatoid Granulomatosis:

Name: Lymphomatoid Granulomatosis 20 58 54 37 70
Lyg 58


Orphanet epidemiological data:

lymphomatoid granulomatosis
Inheritance: Not applicable; Age of onset: Adult;


Orphanet: 58  
Rare haematological diseases

External Ids:

MESH via Orphanet 45 D008230
ICD10 via Orphanet 33 C83.8
UMLS via Orphanet 71 C0024307
Orphanet 58 ORPHA86869
UMLS 70 C0024307

Summaries for Lymphomatoid Granulomatosis

GARD : 20 Lymphomatoid granulomatosis is a rare disorder characterized by an overproduction of white blood cells known as B lymphocytes. These B cells can build up in the tissues of the body, causing damage to the blood vessels. In many cases of lymphomatoid granulomatosis, the abnormal B cells contain the Epstein-Barr virus. The disease is more common in men, usually after the fifth decade of life. Lymphomatoid granulomatosis most commonly affects the lungs, though other areas of the body may also be affected. Signs and symptoms vary but can include cough, shortness of breath, tightness of the chest, fever, weight loss, and fatigue. Skin lesions and central nervous system changes such as headaches, seizures, and ataxia may also be seen. Rarely, the disorder can affect the kidneys or liver. The cause of the disorder is not well understood, though a combination of genetic and immune factors are thought to play a part. Treatment depends on the extent of the disease but may include interferon alfa-2b and combination chemotherapy with rituximab. Occasionally, the disorder resolves on its own without treatment. There has been some debate as to whether lymphomatoid granulomatosis should be viewed as a as a B-cell lymphoma or a lymphoproliferative disease or whether it should be viewed merely as a condition that can develop into a B-cell lymphoma. The prognosis is variable, though lymphomatoid granulomatosis can progress and become fatal in some cases.

MalaCards based summary : Lymphomatoid Granulomatosis, also known as lyg, is related to splenomegaly and lethal midline granuloma, and has symptoms including fever and malaise. An important gene associated with Lymphomatoid Granulomatosis is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Allograft rejection and Immune response Role of DAP12 receptors in NK cells. The drugs Vorinostat and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone marrow and liver.

Wikipedia : 73 Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized... more...

Related Diseases for Lymphomatoid Granulomatosis

Diseases related to Lymphomatoid Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 splenomegaly 30.3 IFNA2 IFNA1
2 lethal midline granuloma 30.1 TIA1 GZMB
3 acquired immunodeficiency syndrome 30.1 IFNA2 IFNA1
4 panniculitis 29.9 TIA1 GZMB
5 peripheral t-cell lymphoma 29.8 TIA1 GZMB
6 mature t-cell and nk-cell lymphoma 29.8 TIA1 GZMB
7 lymphoma, hodgkin, classic 29.8 TIA1 GZMB
8 lymphomatoid papulosis 29.7 TIA1 GZMB
9 erythema multiforme 29.7 TIA1 GZMB
10 angioimmunoblastic t-cell lymphoma 29.6 TIA1 GZMB
11 viral infectious disease 29.5 IFNA2 IFNA1 GZMB
12 mycosis fungoides 28.4 TIA1 IFNA2 IFNA1 GZMB CXCL9
13 lymphoproliferative syndrome 1 11.3
14 lymphoproliferative syndrome, x-linked, 1 11.2
15 lymphoproliferative syndrome 10.9
16 b-cell lymphoma 10.6
17 vasculitis 10.6
18 diffuse large b-cell lymphoma 10.5
19 lymphoma 10.4
20 sarcoidosis 1 10.4
21 rheumatoid arthritis 10.4
22 polymorphic reticulosis 10.4
23 exanthem 10.3
24 granulomatosis with polyangiitis 10.3
25 respiratory failure 10.3
26 leukemia, acute lymphoblastic 10.2
27 pancytopenia 10.2
28 pneumonia 10.2
29 lung disease 10.2
30 immune deficiency disease 10.2
31 wiskott-aldrich syndrome 10.2
32 aphasia 10.2
33 leukemia 10.2
34 agammaglobulinemia 10.2
35 arthritis 10.2
36 crohn's disease 10.2
37 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.2
38 retroperitoneal fibrosis 10.2
39 kaposi sarcoma 10.1
40 leukemia, chronic lymphocytic 10.1
41 leprosy 3 10.1
42 leukemia, acute myeloid 10.1
43 hemophagocytic lymphohistiocytosis 10.1
44 crohn's colitis 10.1
45 childhood acute lymphocytic leukemia 10.1
46 parkinsonism 10.1
47 pleurisy 10.1
48 hemiplegia 10.1
49 richter's syndrome 10.1
50 histoplasmosis 10.1

Graphical network of the top 20 diseases related to Lymphomatoid Granulomatosis:

Diseases related to Lymphomatoid Granulomatosis

Symptoms & Phenotypes for Lymphomatoid Granulomatosis

UMLS symptoms related to Lymphomatoid Granulomatosis:

fever; malaise

Drugs & Therapeutics for Lymphomatoid Granulomatosis

Drugs for Lymphomatoid Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
alemtuzumab Approved, Investigational Phase 2 216503-57-0
Gemcitabine Approved Phase 2 95058-81-4 60750
Melphalan Approved Phase 2 148-82-3 4053 460612
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
Iron Approved Phase 2 7439-89-6 23925 29936
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381 214348
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
nivolumab Approved Phase 2 946414-94-4
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
Busulfan Approved, Investigational Phase 2 55-98-1 2478
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
Oblimersen Experimental, Investigational Phase 2 190977-41-4
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
Alvocidib Experimental, Investigational Phase 1, Phase 2 146426-40-6, 131740-09-5 5287969
32 Histone Deacetylase Inhibitors Phase 1, Phase 2
33 Dermatologic Agents Phase 2
34 Cyclosporins Phase 2
35 Antifungal Agents Phase 2
Isophosphamide mustard Phase 1, Phase 2 100427
37 Vitamin B9 Phase 2
38 Folic Acid Antagonists Phase 2
39 Neuroprotective Agents Phase 2
40 Methylprednisolone Acetate Phase 2
41 Vitamin B Complex Phase 2
42 Folate Phase 2
43 Respiratory System Agents Phase 2
44 Anti-Asthmatic Agents Phase 2
Beclomethasone Phase 2 4419-39-0 20469
46 Bendamustine Hydrochloride Phase 1, Phase 2
47 Chelating Agents Phase 2
48 Iron Chelating Agents Phase 2
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
50 interferons Phase 2

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
2 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
3 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
4 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
5 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
6 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
7 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
8 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
9 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
10 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
11 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
12 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
13 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
14 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
15 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
16 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
17 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
18 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
19 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
20 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
21 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
22 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
23 Treatment and Natural History Study of Lymphomatoid Granulomatosis Recruiting NCT00001379 Phase 2 Rituxan and EPOCH
24 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
25 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
26 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
27 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Active, not recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
28 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Terminated NCT01805037 Phase 1, Phase 2 brentuximab vedotin
29 Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma Terminated NCT00089076 Phase 1, Phase 2
30 A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma Terminated NCT00112723 Phase 1, Phase 2 alvocidib
31 RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) Terminated NCT01044745 Phase 2 rituximab;mycophenolate mofetil;tacrolimus;anti-thymocyte globulin;cyclophosphamide;fludarabine phosphate;busulfan
33 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
34 A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
35 Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
36 A Phase 1 Study of PXD101 in Combination With Bortezomib (PS-341) in Patients With Advanced Solid Tumors and Lymphoma Completed NCT00348985 Phase 1 belinostat;bortezomib
37 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995, IND 61,198), in Combination With 13-Cis-Retinoic Acid in Metastatic Progressive Cancer. Completed NCT00098891 Phase 1 entinostat;isotretinoin
38 Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies Completed NCT00458731 Phase 1 cediranib maleate
39 A Phase I Pharmacokinetic Study of PS341 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group Completed NCT00054483 Phase 1 bortezomib
40 Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction Completed NCT00499811 Phase 1 vorinostat
41 A Phase 1 Study of RO4929097 (NSC749225) in Combination With Capecitabine in Refractory Solid Tumors Completed NCT01158274 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;capecitabine
42 A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors Completed NCT00891072 Phase 1 R-(-)-gossypol acetic acid;paclitaxel;carboplatin
43 A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-B-D-arabinofuranosyl) Uracil, NSC#678515) in Patients With Advanced Solid Tumors Completed NCT00769288 Phase 1 2'-F-ara-deoxyuridine
45 Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma Completed NCT01129193 Phase 1 AR-42
46 A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies Completed NCT01254578 Phase 1 Lenalidomide
47 A Phase 1 Study of SAHA (NSC# 701852) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refractory Solid Tumors Completed NCT00217412 Phase 1 vorinostat;isotretinoin
48 Pharmacokinetic and Phase I Study of Sorafenib (BAY 43-9006, NSC 724772, IND 69896) for Solid Tumors and Hematologic Malignancies in Patients With Hepatic or Renal Dysfunction Completed NCT00118170 Phase 1 sorafenib tosylate
49 A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
50 A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206

Search NIH Clinical Center for Lymphomatoid Granulomatosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Interferon Alfa-2b

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphomatoid Granulomatosis cell therapies at LifeMap Discovery.

Genetic Tests for Lymphomatoid Granulomatosis

Anatomical Context for Lymphomatoid Granulomatosis

MalaCards organs/tissues related to Lymphomatoid Granulomatosis:

B Cells, Bone Marrow, Liver, T Cells, Bone, Lymph Node, Myeloid

Publications for Lymphomatoid Granulomatosis

Articles related to Lymphomatoid Granulomatosis:

(show top 50) (show all 737)
# Title Authors PMID Year
The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. 54 61
9354680 1997
[Lymphomatoid granulomatosis--remission induction with interferon-alpha 2b]. 61 54
9340250 1997
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. 54 61
8639820 1996
The Role and Pitfall of F18-FDG PET/CT in Surveillance of High Grade Pulmonary Lymphomatoid Granulomatosis. 61
30826140 2021
Primary central nervous system lymphomatoid granulomatosis: a case report. 61
33083935 2021
Angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat, with cutaneous and ocular metastasis. 61
33568011 2021
A case of central nervous system lesion pathologically characterized by angiocentric, T-cell-rich lymphoid cell infiltrates: a case report and literature review. 61
33783654 2021
Lymphomatoid granulomatosis in one patient with newly diagnosed HIV infection and Kaposi's sarcoma: a case report and literature review. 61
33777257 2021
EBV Positive Lymphomatoid Granulomatosis Following Dental Extractions. 61
33634720 2021
Chronic lymphocytic infiltration with pontine perivascular enhancement responsive to steroids (CLIPPERS) and its association with Epstein-Barr Virus (EBV)-related lymphomatoid granulomatosis: a case report. 61
33602163 2021
Primary Pulmonary B-Cell Lymphoma: A Review and Update. 61
33499258 2021
A case of resected pulmonary lymphomatoid granulomatosis. 61
33437613 2021
Neuroimages and Neuropathology of a Stroke-Like Cerebral Lymphomatoid Granulomatosis. 61
32624028 2021
An atypical case of a pulmonary mass in an immunocompromised patient. 61
31423951 2020
Primary lymphomatoid granulomatosis of the central nervous system: A diagnostic challenge. 61
33077291 2020
Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement. 61
32900727 2020
A rare case of severe right heart failure due to pulmonary artery lymphomatoid granulomatosis. 61
32964628 2020
Lymphomatoid granulomatosis: a mimicker of systemic inflammatory rheumatological disease. 61
32669017 2020
Extranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia: Case report for a new perspective on Richter syndrome. 61
32384485 2020
Pulmonary Recurrence of Lymphomatoid Granulomatosis Diagnosed on F-18 FDG PET/CT. 61
32351275 2020
Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. 61
32107539 2020
[A Case of Primary Central Nervous System Lymphomatoid Granulomatosis that was Completely Ameliorated by Corticosteroid Treatment]. 61
32036342 2020
Primary Central Nervous System Lymphomatoid Granulomatosis: Systemic Review. 61
33041962 2020
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
A Case Report of a Female Patient With Hodgkin Lymphoma Localized in the Central Nervous System and With Concomitant Pulmonary Lymphomatoid Granulomatosis. 61
33013640 2020
Pulmonary Lymphomatoid Granulomatosis With Hemophagocytic Lymphohistiocytosis as the Initial Manifestation. 61
32064234 2020
Isolated lymphomatoid granulomatosis of the central nervous system: A case report and literature review. 61
31746046 2019
Simultaneous Presentation of Lymphomatoid Granulomatosis and Multiple myeloma in an Immunodeficient Patient with Rheumatoid Arthritis. 61
31243219 2019
An update on IgG4-related lung disease. 61
31227290 2019
Oral Manifestation of Lymphomatoid Granulomatosis. 61
29542064 2019
A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn's disease. 61
31021160 2019
A Case of Methotrexate-Associated Lymphoproliferative Disorder (Lymphomatoid Granulomatosis) of the Skin. 61
31112139 2019
Lymphomatoid granulomatosis mimicking cancer and sarcoidosis. 61
30288554 2019
Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. 61
30284019 2019
Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. 61
30828876 2019
Lymphomatoid granulomatosis: a rare lymphoproliferative disease in the pediatric age. 61
30337062 2019
Cutaneous lymphomatoid granulomatosis with long-term absence of lung involvement. 61
30010204 2019
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. 61
29982850 2019
Lymphomatoid Granulomatosis in a Patient with Chronic Lymphocytic Leukemia and Rapidly Progressing Peribronchovascular Pulmonary Infiltrates. 61
30805241 2019
Magnesium Restores Activity to Peripheral Blood Cells in a Patient With Functionally Impaired Interleukin-2-Inducible T Cell Kinase. 61
31507602 2019
Pitfall of 18F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis. 61
29884684 2018
Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. 61
30292067 2018
Case 259: Primary Central Nervous System Lymphomatoid Granulomatosis Mimicking Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). 61
30332362 2018
The Spontaneous Regression of Grade 3 Methotrexate-related Lymphomatoid Granulomatosis: A Case Report and Literature Review. 61
29877270 2018
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. 61
29473430 2018
Lymphomatoid Granulomatosis with Isolated Cutaneous Lesions: Prolonged Remission After DA-EPOCH Protocol 61
29856361 2018
Cartilage hair hypoplasia with cutaneous lymphomatoid granulomatosis. 61
29744913 2018
Primary pulmonary lymphoproliferative neoplasms. 61
29697079 2018
Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report. 61
29739366 2018
Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. 61
29635846 2018

Variations for Lymphomatoid Granulomatosis

Expression for Lymphomatoid Granulomatosis

Search GEO for disease gene expression data for Lymphomatoid Granulomatosis.

Pathways for Lymphomatoid Granulomatosis

Pathways related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
3 11.28 IFNA2 IFNA1
4 10.93 IFNA2 IFNA1
5 10.72 IFNA2 CXCL9

GO Terms for Lymphomatoid Granulomatosis

Biological processes related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.69 TIA1 IFNA2 GZMB
2 negative regulation of translation GO:0017148 9.49 TIA1 GZMB
3 B cell differentiation GO:0030183 9.48 IFNA2 IFNA1
4 type I interferon signaling pathway GO:0060337 9.46 IFNA2 IFNA1
5 humoral immune response GO:0006959 9.43 IFNA2 IFNA1
6 response to exogenous dsRNA GO:0043330 9.4 IFNA2 IFNA1
7 B cell proliferation GO:0042100 9.37 IFNA2 IFNA1
8 T cell activation involved in immune response GO:0002286 9.32 IFNA2 IFNA1
9 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNA2 IFNA1
10 natural killer cell activation involved in immune response GO:0002323 9.16 IFNA2 IFNA1
11 defense response to virus GO:0051607 9.13 IFNA2 IFNA1 CXCL9
12 defense response GO:0006952 8.8 IFNA2 IFNA1 CXCL9

Molecular functions related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA2 IFNA1
2 cytokine activity GO:0005125 9.13 IFNA2 IFNA1 CXCL9
3 type I interferon receptor binding GO:0005132 8.62 IFNA2 IFNA1

Sources for Lymphomatoid Granulomatosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....